|
66
|
225
|
7n8mA |
Pptt pap(coa) 8978b complex |
|
92
|
267
|
6j6mA |
Co-crystal structure of btk kinase domain with zanubrutinib |
|
83
|
281
|
7lqdA |
Structure of human mps1 (ttk) covalently bound to rms-07 inhibitor |
|
81
|
305
|
7rj6A |
Crystal structure of ap2 associated kinase 1 isoform 1 complexed with ligand (2r)-2-amino-n-[3-(difluorom ethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide |
|
81
|
307
|
7ky0A |
Inactive conformation of egfr (t790m/v948r) kinase in complex with bi-4020 |
|
91
|
322
|
7kxzA |
Active conformation of egfr kinase in complex with bi-4020 |
|
78
|
305
|
7lg8A |
Egfr (t79m/v948r) in complex with naquotinib and an allosteric inhibitor |
|
161
|
420
|
5sc9A |
Structure of liver pyruvate kinase in complex with anthraquinone derivative 29 |
|
165
|
420
|
5scaA |
Structure of liver pyruvate kinase in complex with anthraquinone derivative 36 |
|
162
|
420
|
5sc8A |
Structure of liver pyruvate kinase in complex with anthraquinone derivative 17 |
|
165
|
420
|
5sdtA |
Structure of liver pyruvate kinase in complex with anthraquinone derivative 15 |
|
167
|
423
|
5scjA |
Structure of liver pyruvate kinase in complex with anthraquinone derivative 106 |
|
163
|
420
|
5sckA |
Structure of liver pyruvate kinase in complex with anthraquinone derivative 42 |
|
163
|
423
|
5sciA |
Structure of liver pyruvate kinase in complex with anthraquinone derivative 105 |
|
162
|
420
|
5scbA |
Structure of liver pyruvate kinase in complex with anthraquinone derivative 28 |
|
163
|
420
|
5sccA |
Structure of liver pyruvate kinase in complex with anthraquinone derivative 57 |
|
166
|
420
|
5sclA |
Structure of liver pyruvate kinase in complex with anthraquinone derivative 1 |
|
161
|
420
|
5sceA |
Structure of liver pyruvate kinase in complex with anthraquinone derivative 55 |
|
164
|
420
|
5scgA |
Structure of liver pyruvate kinase in complex with anthraquinone derivative 101 |
|
163
|
420
|
5scfA |
Structure of liver pyruvate kinase in complex with anthraquinone derivative 99 |
|
160
|
420
|
5schA |
Structure of liver pyruvate kinase in complex with anthraquinone derivative 100 |
|
161
|
420
|
5scdA |
Structure of liver pyruvate kinase in complex with anthraquinone derivative 58 |
|
97
|
323
|
7vreA |
The crystal structure of egfr t790m/c797s with the inhibitor hcd2892 |
|
93
|
323
|
7vraA |
The crystal structure of egfr t790m/c797s with the inhibitor hc5476 |
|
97
|
348
|
7u2zA |
Crystal structure of human gsk3b in complex with g12 |
|
101
|
350
|
7u31A |
Crystal structure of human gsk3b in complex with g5 |
|
106
|
350
|
7u33A |
Crystal structure of human gsk3b in complex with arn9133 |
|
102
|
350
|
7u36A |
Crystal structure of human gsk3b in complex with arn1484 |
|
266
|
939
|
7r9yA |
Structure of pik3ca with covalent inhibitor 22 |
|
268
|
939
|
7r9vA |
Structure of pik3ca with covalent inhibitor 19 |
|
57
|
214
|
7sanA |
Crystal structure of human hypoxanthine guanine phosphoribzosyltransferase in complex with (4s,7s)-7-hydroxy-4-((guanin-9-yl)methyl)-2,5-dioxaheptan-1,7-diphosphonate |
|
87
|
266
|
7n4rA |
Bruton's tyrosine kinase in complex with compound 21 |
|
85
|
265
|
7n4sA |
Bruton's tyrosine kinase in complex with compound 65 |
|
85
|
268
|
7l5pA |
Crystal structure of the covalently bonded complex of rilzabrutinib with btk |
|
87
|
267
|
7n4qA |
Bruton's tyrosine kinase in complex with compound 45 |
|
91
|
270
|
7l5oA |
Crystal structure of the noncovalently bonded complex of rilzabrutinib with btk |
|
87
|
304
|
5sb2A |
Ddr1, 3-chloro-n-[(1r,2s)-2-phenylcyclopropyl]-5-(1h-pyrrolo[2,3-b]pyridin-5-yloxymethyl)benzamide, 1.600a, p212121, rfree=23.2% |
|
92
|
307
|
5saxA |
Ddr1, 2-[3-(2-pyridin-3-ylethynyl)phenyl]-n-[3-(trifluoromethyl)phenyl]acetamide, 1.902a, second p212121 form, rfree=25.4%, second form |
|
94
|
299
|
5sawA |
Ddr1, 2-[3-(2-pyridin-3-ylethynyl)phenyl]-n-[3-(trifluoromethyl)phenyl]acetamide, 1.601a, p212121, rfree=22.6% |
|
89
|
303
|
5sauA |
Ddr1, 3-[2-(6-aminopyridin-3-yl)ethynyl]-n-[3-(trifluoromethyl)phenyl]benzamide, 1.800a, p212121, rfree=23.1% |
|
89
|
300
|
5sayA |
Ddr1, n-[2-[3-(2-aminopyrimidin-5-yl)oxyphenyl]ethyl]-3-(trifluoromethoxy)benzamide, 2.190a, p1211, rfree=27.7% |
|
99
|
302
|
5savA |
Ddr1, n-[2-[3-(2-aminopyrimidin-5-yl)oxyphenyl]ethyl]-3-(trifluoromethoxy)benzamide, 1.760a, p212121, rfree=23.5% |
|
89
|
304
|
5sb1A |
Ddr1, 4-chloro-n-[(3s,4r)-4-phenylpyrrolidin-3-yl]-3-(1h-pyrrolo[2,3-b]pyridin-5-yloxymethyl)benzamide, 1.530a, p212121, rfree=21.4% |
|
90
|
304
|
5sb0A |
Ddr1, n-[[2-(2-pyridin-3-yloxyethyl)cyclohexyl]methyl]-3-(trifluoromethoxy)benzamide, 1.970a, p212121, rfree=25.6% |
|
96
|
305
|
5sazA |
Ddr1, 3-chloro-n-[4-chloro-3-(1h-pyrrolo[2,3-b]pyridin-5-ylcarbamoyl)phenyl]-4-(2-hydroxyethylamino)benzamide, 1.802a, p212121, rfree=22.2% |
|
318
|
1060
|
8tduA |
Stx-478, a mutant-selective, allosteric inhibitor bound to pi3kalpha |
|
137
|
416
|
8esmA |
Human triacylglycerol synthesizing enzyme dgat1 in complex with t863 inhibitor |
|
76
|
259
|
8tduB |
Stx-478, a mutant-selective, allosteric inhibitor bound to pi3kalpha |
|
97
|
325
|
8f1zA |
Egfr kinase in complex with bayer #33 |
|
82
|
307
|
8f1wA |
Egfr(t790m/v948r) kinase in complex with poziotinib |
